Study where pharmaco magnetic resonance imaging (MRI) effects of AZD6765 will be compared to placebo in depressive male and female subjects
Study identifier:D2285C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female subjects fulfilling the criteria for major depressive disorder
Medical condition
Depression
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6765, Ketamine, Placebo
Sex
All
Actual Enrollment
128
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Dec 2009
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
University of Manchester, University of Oxford
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 single infusion | Drug: AZD6765 single infusion |
| Active Comparator: 2 single infusion | Drug: Ketamine single infusion |
| Placebo Comparator: 3 single infusion | Drug: Placebo single infusion |
Contacts
Investigators
Principal Investigator
Bill Deakin
University of Manchester, Neurosciance and Psychiatry Unit, UK
